Press coverage about DBV Technologies (NASDAQ:DBVT) has trended somewhat positive this week, Accern reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DBV Technologies earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.4542770399447 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of equities research analysts have recently issued reports on the company. BidaskClub upgraded DBV Technologies from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 21st. Zacks Investment Research upgraded DBV Technologies from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research note on Tuesday. ValuEngine cut DBV Technologies from a “hold” rating to a “sell” rating in a research note on Friday, June 30th. Leerink Swann upped their price objective on DBV Technologies from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Friday, August 25th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of DBV Technologies in a research note on Monday, July 10th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. DBV Technologies has an average rating of “Buy” and a consensus target price of $50.00.

Shares of DBV Technologies (NASDAQ:DBVT) opened at 44.04 on Wednesday. DBV Technologies has a 1-year low of $31.87 and a 1-year high of $46.33. The company has a 50-day moving average price of $43.12 and a 200-day moving average price of $36.84. The company’s market cap is $2.03 billion.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect DBV Technologies (DBVT) Share Price” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/30/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-dbv-technologies-dbvt-share-price.html.

About DBV Technologies

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Insider Buying and Selling by Quarter for DBV Technologies (NASDAQ:DBVT)

Receive News & Stock Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related stocks with our FREE daily email newsletter.